CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: SLC25A27 (ImmuneEditome ID:9481)

1. Gene summary of enriched editing regions for SLC25A27

check button Gene summary
Gene informationGene symbol

SLC25A27

Gene ID

9481

GeneSynonymsUCP4
GeneCytomap

6p12.3

GeneTypeprotein-coding
GeneDescriptionmitochondrial uncoupling protein 4|UCP 4|uncoupling protein 4
GeneModificationdate20230329
UniprotIDO95847;Q5VTS8
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr6:46656201-46657433:+ENST00000371347.8ENSG00000153291.14SLC25A27intronicAluSq2,L1MC5a,AluSx,AluJochr6:46656201-46657433:+.alignment
chr6:46656201-46657433:+ENST00000411689.5ENSG00000153291.14SLC25A27intronicAluSq2,L1MC5a,AluSx,AluJochr6:46656201-46657433:+.alignment


Top

2. Tumor-specific enriched editing regions for SLC25A27


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr6:46656201-46657433:+SKCMPathEER1.1380e-025.0497e-030.2632image
ENSG00000153291.14,SLC25A27SKCMPathEAG1.1380e-025.0497e-030.2632image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr6:46656201-46657433:+KIRPEER2.9903e-039.9141e-031.3763e+10image
ENSG00000153291.14,SLC25A27KIRPEAG2.9903e-039.9141e-031.3763e+10image
chr6:46656201-46657433:+OVEER1.6039e-048.3645e-042.6511e+01image
ENSG00000153291.14,SLC25A27OVEAG1.6039e-049.8032e-042.5243e+01image

Top

3. Enriched editing regions and immune related genes for SLC25A27


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for SLC25A27


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

5. Enriched editing regions and immune infiltration for SLC25A27


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr6:46656201-46657433:+BLCAEERDendritic_cells_resting2.1972e-020.5088image
ENSG00000153291.14,SLC25A27BLCAEAGDendritic_cells_resting2.1972e-020.5088image
chr6:46656201-46657433:+BRCAEERMast_cells_resting1.3058e-030.3338image
ENSG00000153291.14,SLC25A27BRCAEAGMast_cells_resting1.2399e-030.3352image
chr6:46656201-46657433:+CESCEERDendritic_cells_resting3.4685e-020.4741image
ENSG00000153291.14,SLC25A27CESCEAGDendritic_cells_resting3.4685e-020.4741image
chr6:46656201-46657433:+ESCAEERNK_cells_resting1.8889e-020.3697image
ENSG00000153291.14,SLC25A27ESCAEAGNK_cells_resting1.9218e-020.3687image
chr6:46656201-46657433:+KIRCEERMast_cells_resting2.2852e-02-0.2169image
ENSG00000153291.14,SLC25A27KIRCEAGMast_cells_resting3.4512e-02-0.2009image
chr6:46656201-46657433:+KIRPEERMacrophages_M23.7864e-02-0.2205image
ENSG00000153291.14,SLC25A27KIRPEAGMacrophages_M23.7864e-02-0.2205image
chr6:46656201-46657433:+LUADEERT_cells_CD84.0468e-020.2676image
ENSG00000153291.14,SLC25A27LUADEAGT_cells_CD84.1441e-020.2663image
chr6:46656201-46657433:+LUSCEERT_cells_regulatory_(Tregs)2.2576e-020.4220image
ENSG00000153291.14,SLC25A27LUSCEAGT_cells_regulatory_(Tregs)2.2576e-020.4220image
chr6:46656201-46657433:+OVEERNeutrophils3.7001e-02-0.2413image
ENSG00000153291.14,SLC25A27OVEAGNeutrophils3.4913e-02-0.2440image
chr6:46656201-46657433:+PAADEERDendritic_cells_activated9.9437e-03-0.5260image
ENSG00000153291.14,SLC25A27PAADEAGDendritic_cells_activated9.9437e-03-0.5260image
chr6:46656201-46657433:+PCPGEERT_cells_follicular_helper4.4702e-02-0.2646image
ENSG00000153291.14,SLC25A27PCPGEAGT_cells_follicular_helper4.4904e-02-0.2644image
chr6:46656201-46657433:+PRADEERDendritic_cells_activated2.7506e-02-0.1411image
ENSG00000153291.14,SLC25A27PRADEAGDendritic_cells_activated2.7481e-02-0.1412image
chr6:46656201-46657433:+SARCEERPlasma_cells2.1517e-020.4765image
ENSG00000153291.14,SLC25A27SARCEAGPlasma_cells2.1517e-020.4765image
chr6:46656201-46657433:+STADEERT_cells_regulatory_(Tregs)2.5176e-020.2638image
ENSG00000153291.14,SLC25A27STADEAGT_cells_regulatory_(Tregs)2.4176e-020.2655image


Top

6. Enriched editing regions and immune gene sets for SLC25A27


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000153291.14,SLC25A27BLCAGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG4.6983e-030.6051image
chr6:46656201-46657433:+BLCAGSVA_HALLMARK_TGF_BETA_SIGNALINGEER4.6983e-030.6051image
ENSG00000153291.14,SLC25A27BRCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG5.1942e-050.4131image
chr6:46656201-46657433:+BRCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER5.7848e-050.4108image
ENSG00000153291.14,SLC25A27CESCGSVA_HALLMARK_MYOGENESISEAG1.1906e-030.6714image
chr6:46656201-46657433:+CESCGSVA_HALLMARK_MYOGENESISEER1.1906e-030.6714image
chr6:46656201-46657433:+COADGSVA_HALLMARK_APICAL_SURFACEEER3.1088e-020.2509image
ENSG00000153291.14,SLC25A27COADGSVA_HALLMARK_APICAL_SURFACEEAG2.6425e-020.2581image
chr6:46656201-46657433:+ESCAGSVA_HALLMARK_IL2_STAT5_SIGNALINGEER1.8244e-02-0.3716image
ENSG00000153291.14,SLC25A27ESCAGSVA_HALLMARK_IL2_STAT5_SIGNALINGEAG1.8044e-02-0.3722image
ENSG00000153291.14,SLC25A27GBMGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG1.2120e-020.5367image
chr6:46656201-46657433:+GBMGSVA_HALLMARK_FATTY_ACID_METABOLISMEER1.2200e-020.5363image
ENSG00000153291.14,SLC25A27KIRCGSVA_HALLMARK_UV_RESPONSE_UPEAG2.8606e-030.2805image
chr6:46656201-46657433:+KIRCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.0197e-030.2913image
chr6:46656201-46657433:+LGGGSVA_HALLMARK_COAGULATIONEER4.0801e-040.2223image
ENSG00000153291.14,SLC25A27LGGGSVA_HALLMARK_COAGULATIONEAG4.0801e-040.2223image
chr6:46656201-46657433:+LUADGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER1.0029e-020.3327image
ENSG00000153291.14,SLC25A27LUADGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG9.9521e-030.3330image
chr6:46656201-46657433:+LUSCGSVA_HALLMARK_P53_PATHWAYEER5.1355e-040.6046image
ENSG00000153291.14,SLC25A27LUSCGSVA_HALLMARK_P53_PATHWAYEAG5.1355e-040.6046image
ENSG00000153291.14,SLC25A27OVGSVA_HALLMARK_ANDROGEN_RESPONSEEAG6.8098e-060.4936image
chr6:46656201-46657433:+OVGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER5.6543e-060.4973image
ENSG00000153291.14,SLC25A27PAADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.7434e-030.6162image
chr6:46656201-46657433:+PAADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.7434e-030.6162image
chr6:46656201-46657433:+PRADGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER5.9373e-060.2853image
ENSG00000153291.14,SLC25A27PRADGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG6.7158e-060.2838image
ENSG00000153291.14,SLC25A27READGSVA_HALLMARK_MYC_TARGETS_V1EAG2.2778e-020.4942image
chr6:46656201-46657433:+READGSVA_HALLMARK_MYC_TARGETS_V1EER2.2778e-020.4942image
chr6:46656201-46657433:+SKCMGSVA_HALLMARK_HYPOXIAEER1.9583e-020.2053image
ENSG00000153291.14,SLC25A27SKCMGSVA_HALLMARK_HYPOXIAEAG1.9583e-020.2053image
ENSG00000153291.14,SLC25A27THCAGSVA_HALLMARK_PEROXISOMEEAG5.7428e-040.2324image
chr6:46656201-46657433:+THCAGSVA_HALLMARK_PEROXISOMEEER6.7822e-040.2295image


Top

7. Enriched editing regions and drugs for SLC25A27


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000153291.14,SLC25A27BRCABAY.61.3606EAG9.1873e-050.4026image
chr6:46656201-46657433:+BRCABAY.61.3606EER1.0882e-040.3987image
ENSG00000153291.14,SLC25A27CESCGW.441756EAG1.0007e-020.5614image
chr6:46656201-46657433:+CESCGW.441756EER1.0007e-020.5614image
chr6:46656201-46657433:+COADEtoposideEER1.9211e-030.3548image
ENSG00000153291.14,SLC25A27COADEtoposideEAG1.6089e-030.3604image
ENSG00000153291.14,SLC25A27KIRCCCT007093EAG1.8099e-040.3481image
chr6:46656201-46657433:+KIRCCCT007093EER7.3676e-050.3688image
chr6:46656201-46657433:+KIRPJW.7.52.1EER7.6964e-03-0.2808image
ENSG00000153291.14,SLC25A27KIRPJW.7.52.1EAG7.6964e-03-0.2808image
chr6:46656201-46657433:+LGGAZ628EER6.6271e-05-0.2500image
ENSG00000153291.14,SLC25A27LGGAZ628EAG6.6271e-05-0.2500image
chr6:46656201-46657433:+LUADAG.014699EER8.3118e-050.4896image
ENSG00000153291.14,SLC25A27LUADAG.014699EAG8.9570e-050.4876image
chr6:46656201-46657433:+LUSCAZD6244EER6.7796e-03-0.4915image
ENSG00000153291.14,SLC25A27LUSCAZD6244EAG6.7796e-03-0.4915image
ENSG00000153291.14,SLC25A27OVGNF.2EAG1.7206e-05-0.4743image
chr6:46656201-46657433:+OVGNF.2EER1.1581e-05-0.4826image
ENSG00000153291.14,SLC25A27PAADMethotrexateEAG6.4360e-030.5746image
chr6:46656201-46657433:+PAADMethotrexateEER6.4360e-030.5746image
chr6:46656201-46657433:+PRADBMS.509744EER7.8530e-06-0.2817image
ENSG00000153291.14,SLC25A27PRADBMS.509744EAG8.7795e-06-0.2803image
ENSG00000153291.14,SLC25A27READDMOGEAG1.1387e-020.5407image
chr6:46656201-46657433:+READDMOGEER1.1387e-020.5407image
chr6:46656201-46657433:+SARCAMG.706EER2.4016e-03-0.6014image
ENSG00000153291.14,SLC25A27SARCAMG.706EAG2.4016e-03-0.6014image
chr6:46656201-46657433:+SKCMBryostatin.1EER1.7807e-02-0.2084image
ENSG00000153291.14,SLC25A27SKCMBryostatin.1EAG1.7807e-02-0.2084image
ENSG00000153291.14,SLC25A27STADLenalidomideEAG3.0987e-03-0.3439image
chr6:46656201-46657433:+STADLenalidomideEER3.1007e-03-0.3439image
ENSG00000153291.14,SLC25A27THCABIRB.0796EAG4.6525e-020.1356image
chr6:46656201-46657433:+THCABIRB.0796EER4.5262e-020.1364image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType